NAMPT serum levels are selectively elevated in acute infectious disease and in acute relapse of chronic inflammatory diseases in children

PLoS One. 2017 Aug 24;12(8):e0183027. doi: 10.1371/journal.pone.0183027. eCollection 2017.

Abstract

Nicotinamide phosphoribosyl transferase (NAMPT) is an inflammatory adipocytokine shown to interact in immune modulation in chronic inflammatory diseases, acute respiratory distress syndrome, sepsis, cancer and obesity in adulthood. It is, however, not clear whether this association reflects a chronic elevation or acute inflammatory response. We analyzed NAMPT concentrations in distinct states of inflammation in 102 children and found consistently significantly increased NAMPT levels in subjects with acute infections. NAMPT concentrations in children with stable chronic inflammatory diseases were not significantly different, whereas in patients with acute relapse of chronic disease NAMPT was significantly higher than in children in remission or healthy controls. In states of low-grade inflammation (children with atopic disease or obesity) we did not detect alterations in NAMPT serum levels. NAMPT correlated positively with inflammatory markers such as CRP. The most predictive factor for NAMPT serum concentrations was leucocyte count and therein the neutrophil count. Furthermore, systemic circulating NAMPT levels were closely associated with NAMPT release from corresponding cultured PBMCs. In conclusion, NAMPT is selectively increased in states of acute but not chronic inflammation in children. The close relationship between systemic circulating NAMPT with leucocyte counts and release indicate that leucocytes most probably are the source of inflammation related NAMPT levels.

MeSH terms

  • Adolescent
  • Child
  • Chronic Disease
  • Cohort Studies
  • Communicable Diseases / blood
  • Communicable Diseases / enzymology*
  • Cytokines / blood*
  • Female
  • Humans
  • Inflammation / blood
  • Inflammation / enzymology*
  • Male
  • Nicotinamide Phosphoribosyltransferase / blood*
  • Recurrence

Substances

  • Cytokines
  • Nicotinamide Phosphoribosyltransferase
  • nicotinamide phosphoribosyltransferase, human

Grants and funding

This work was supported by the German Research Foundation for the Clinical Research Center “Obesity Mechanisms” CRC1052/1 C05 and by the LIFE (Leipzig Research Center for Civilization Diseases, Universität Leipzig), funded by the European Union, by the European Regional Development Fund (ERFD) by means of the Free State of Saxony within the framework of the excellence initiative, and by the Federal Ministry of Education and Research (BMBF), Germany, Integrated Research and Treatment Centre (IFB) Adiposity Diseases FKZ: 01EO1001. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.